The Goldman Sachs Group Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price reduced by equities researchers at The Goldman Sachs Group from $1,019.00 to $917.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price target points to a potential upside […]
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price reduced by equities researchers at The Goldman Sachs Group from $1,019.00 to $917.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price target points to a potential upside […]